Comparison of lopinavir/ritonavir or hydroxychloroquine in patients with mild coronavirus disease (COVID‐19)  Drug: lopinavir/ritonavir, Drug: hydroxychloroquine sulfate  Korea/COVID‐19  150, all, 16 years to 99 years  Treatment  Experimental: lopinavir/ritonavir 200 mg/100 mg 2 tablets by mouth, every 12 hr for 7–10 days
Active comparator: hydroxychloroquine 200 mg 2 tablets by mouth, every 12 hr for 7–10 days
No intervention: control, no lopinavir/ritonavir and hydroxychloroquine  II  Primary: viral load (hospital Day 3, 5, 7, 10, 14, 18)
Secondary viral load change (hospital Day 3, 5, 7, 10, 14, 18), time to clinical improvement (time frame: up to 28 days), percentage of progression to supplemental oxygen requirement by Day 7, Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hr by Day 7, time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission (up to 28 days), rate of switch to lopinavir/ritonavir or hydroxychloroquine by Day 7, adverse effects (up to 28 days), concentration of lopinavir/ritonavir and hydroxychloroquine (1, 2, 4, 5, 12 hr after taking intervention medicine)  NCT04307693/Recruiting, Mar11‐May 2020